Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Daizo Kishino
Phase II Trial of Gefitinib in Combination With Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer With Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Sensitizing EGFR Mutation
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
140PD: LUX-Lung 7: A Phase IIb, Global, Randomised, Open-Label Trial of Afatinib vs Gefitinib as First-Line Treatment for Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) Harbouring Activating EGFR Mutations
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-109 Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients With Non–Small-Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients With Non–Small-Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Randomized Phase II Trial of Seribantumab in Combination With Erlotinib in Patients With EGFR Wild‐Type Non‐Small Cell Lung Cancer
Oncologist
Cancer Research
Medicine
Oncology
First-Line Single Agent Treatment With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer
Journal of Experimental and Clinical Cancer Research
Cancer Research
Oncology
Combination of Chemotherapy and Gefitinib as First-Line Treatment for Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: A Randomized Controlled Trial
International Journal of Cancer
Cancer Research
Oncology
Trial-Based Cost-Utility Analysis of Icotinib Versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China
PLoS ONE
Multidisciplinary
